ProMIS Neurosciences Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
PMN$4.05-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
| · · · · · · · · · · · · · · · · · | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||
| · · · · · · · Additional · · Other · · · · · | |||||||||||||
| · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · | |||||||||||||
| · · Shares · · Amount · · Capital · · Loss · · Deficit · · Total | |||||||||||||
| Balance, January 1, 2025 | | 1,307,568 | | $— | | $107,546,433 | | $(371,184) | | $(90,687,073) | | $16,488,176 | |
| Share-based compensation expense | | — | | — | | 245,295 | | — | | — | | | 245,295 |
| Re-measurement of liability-classified CAD stock options as of March 31, 2025 | | — | | — | | 86,163 | | — | | — | | | 86,163 |
| Net loss | | — | | — | | — | | — | | (7,347,903) | | | (7,347,903) |
| Balance, March 31, 2025 | 1,307,568 | | $— | $107,877,891 | $(371,184) | $(98,034,976) | | $9,471,731 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||
| · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · · | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Loss · · Deficit · · Total | |||||||||||||||||
| Balance, January 1, 2026 | | 2,152,397 | | $— | | $129,518,812 | | $(371,184) | | $(130,406,220) | | $(1,258,592) | |||||
| Share-based compensation expense | | — | | — | | 189,425 | | | — | | | — | | | 189,425 | ||
| Proceeds from issuance of Common Shares, pre-funded warrants, and warrants from January 29, 2026 PIPE, net of issuance costs | | 6,815,296 | | | — | | | 70,081,309 | | | — | | | — | | | 70,081,309 |
| Re-measurement of liability-classified CAD stock options as of March 31, 2026 | | — | | — | | | (50,198) | | | — | | | — | | | (50,198) | |
| Net loss | — | | — | | — | | — | | (8,244,372) | | (8,244,372) | ||||||
| Balance, March 31, 2026 | 8,967,693 | | $— | | $199,739,348 | | $(371,184) | | $(138,650,592) | | $60,717,572 | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.